問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

更新時間：2023-09-19

蔡英明Tsai, Ying-Ming Tsai
  • Principal Investigator
  • Clinical Trial Experience (year) -13 years -4 個月

  • yingming@kmu.edu.tw

Recruiting Trial

83Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蔡英明

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Thoracic Medicine

List

60Cases

2024-01-01 - 2030-06-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

2024-01-01 - 2040-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2024-02-06 - 2029-08-30

Phase II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Not yet recruiting8Sites

Recruiting1Sites

2024-02-26 - 2037-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting3Sites

Recruiting4Sites

2025-02-01 - 2030-12-31

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2025-04-01 - 2027-11-30

Phase I

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2025-08-20 - 2029-02-17

Phase III

Active
AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH PD-L1 HIGH (≥50% OF TUMOR CELLS EXPRESSING PD-L1), LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC NON-SMALL CELL LUNG CANCER (BE6A LUNG-02)

  • Condition/Disease

    Carcinoma, Non-Small-Cell Lung (NSCLC)

  • Test Drug

    凍晶注射劑 注射劑

Participate Sites
8Sites

Recruiting8Sites

2025-09-01 - 2031-08-14

Phase I/II

Active
A Phase Ib/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Recommended Combination Dose of BNT324 With BNT327 in Participants With Advanced Lung Cancer

  • Condition/Disease

    Advanced Lung Cancer

  • Test Drug

    靜脈輸注液 溶液用粉劑

Participate Sites
5Sites

Recruiting5Sites

2025-04-01 - 2033-01-20

Active
A phase 3, multicenter, randomized, open-label trial evaluating trastuzumab deruxtecan plus pembrolizumab versus platinum-based chemotherapy plus pembrolizumab as first-line therapy in participants with locally advanced, unresectable or metastatic HER2 overexpression and PD-L1 TPS <50% non-squamous non-small cell lung cancer (DESTINY-Lung06).

  • Condition/Disease

    The efficacy of T-DXd with pembrolizumab versus platinum-based chemotherapy with pembrolizumab was compared using PFS as assessed by BICR. PFS was defined as the time interval elapsed from the date of randomization to the date of radiographic disease progression or death from any cause. Tumor response was assessed by BICR tumor scans and determined using the Solid Tumor Response Assessment Criteria, version 1.1 (RECIST v1.1).

  • Test Drug

    Trastuzumab Deruxtecan

Participate Sites
9Sites

Recruiting9Sites

2025-04-01 - 2027-12-31

Active
A multicenter, open-label, randomized phase 3 trial evaluating sequential administration of THIO and Cemiplimab (LIBTAYO®) versus single-agent chemotherapy of the trial administrator's choice in advanced/metastatic non-small cell lung cancer (NSCLC).

  • Condition/Disease

    OS (defined as the time elapsed from random assignment to death for any reason)

  • Test Drug

    LIBTAYO THIO

Participate Sites
10Sites

Recruiting10Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB